GALAD (Gender, age, AFP-L3, AFP, and des-carboxy-prothrombin [DCP]), a promising biomarker panel is proved to be excellent for early detection of HCC in NAFLD/NASH patients with and without HCC and GALAD is significantly superior to each individual marker [67]. This evidence concerns the gene AFP and metabolic dysfunction-associated steatohepatitis.